Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurosci ; 38(32): 7088-7099, 2018 08 08.
Article in English | MEDLINE | ID: mdl-29976621

ABSTRACT

Methods to promote myelin regeneration in response to central myelin loss are essential to prevent the progression of clinical disability in demyelinating diseases. The neurotrophin brain-derived neurotrophic factor (BDNF) is known to promote myelination during development via oligodendrocyte expressed TrkB receptors. Here, we use a structural mimetic of BDNF to promote myelin regeneration in a preclinical mouse model of central demyelination. In female mice, we show that selective targeting of TrkB with the BDNF-mimetic enhances remyelination, increasing oligodendrocyte differentiation, the frequency of myelinated axons, and myelin sheath thickness after a demyelinating insult. Treatment with exogenous BDNF exerted an attenuated effect, increasing myelin sheath thickness only. Further, following conditional deletion of TrkB from premyelinating oligodendrocytes, we show the effects of the BDNF-mimetic on oligodendrocyte differentiation and remyelination are lost, indicating these are dependent on oligodendrocyte expression of TrkB. Overall, these studies demonstrate that targeting oligodendrocyte TrkB promotes in vivo remyelination in the brain.SIGNIFICANCE STATEMENT Novel strategies to promote myelin regeneration are required to prevent progressive neurodegeneration and clinical disability in patients with central demyelinating disease. Here, we test whether selectively targeting the TrkB receptor on the myelin-producing oligodendrocytes, can promote remyelination in the brain. Using a structural mimetic of its native ligand, BDNF, we show that stimulation of TrkB enhances remyelination, increasing oligodendrocyte differentiation, the frequency of myelinated axons and thickness of the myelin sheath following a demyelinating insult. Further, we show that these effects are dependent on the phosphorylation of oligodendrocyte expressed TrkB receptors in vivo Overall, we demonstrate that selective targeting of TrkB has therapeutic potential to promote remyelination in the brain.


Subject(s)
Brain-Derived Neurotrophic Factor/therapeutic use , Brain/drug effects , Demyelinating Diseases/drug therapy , Membrane Glycoproteins/agonists , Molecular Targeted Therapy , Myelin Sheath/metabolism , Oligodendroglia/drug effects , Remyelination/drug effects , Animals , Brain/metabolism , Brain/pathology , Brain-Derived Neurotrophic Factor/pharmacology , Cell Division/drug effects , Corpus Callosum/metabolism , Corpus Callosum/pathology , Cuprizone/toxicity , Demyelinating Diseases/chemically induced , Demyelinating Diseases/pathology , Female , Infusion Pumps, Implantable , Infusions, Intraventricular , Male , Membrane Glycoproteins/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Myelin Basic Protein/biosynthesis , Neural Stem Cells/drug effects , Peptides, Cyclic/pharmacology , Peptides, Cyclic/therapeutic use , Phosphorylation , Protein Processing, Post-Translational/drug effects , Protein-Tyrosine Kinases/metabolism , Specific Pathogen-Free Organisms
SELECTION OF CITATIONS
SEARCH DETAIL
...